ダウンロード数: 245
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
39_1139.pdf | 377.72 kB | Adobe PDF | 見る/開く |
タイトル: | 進行前立腺癌に対するEtoposide,Ifosfamide,Peplomycin併用化学療法の治療成績について |
その他のタイトル: | Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer |
著者: | 牛山, 知己 伊原, 博行 栗田, 豊 影山, 慎二 上田, 大介 麦谷, 荘一 山口, 安三 中野, 優 鈴木, 和雄 河邉, 香月 太田, 信隆 田島, 惇 阿曽, 佳郎 |
著者名の別形: | Ushiyama, Tomomi Ihara, Hiroyuki Kurita, Yutaka Kageyama, Shinji Ueda, Daisuke Mugiya, Soichi Yamaguchi, Yasuzo Nakano, Masaru Suzuki, Kazuo Kawabe, Kazuki Ohta, Nobutaka Tajima, Atsushi Aso, Yosio |
キーワード: | Prostatic cancer Combination chemotherapy |
発行日: | Dec-1993 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 39 |
号: | 12 |
開始ページ: | 1139 |
終了ページ: | 1144 |
抄録: | Between August, 1986 and August, 1992, 16 combination chemotherapies with etoposide (100 mg/body, day 1-5), ifosfamide (50 mg/kg, day 1, 3, 5), peplomycin (5 mg/body, day 1-5) were performed on 13 patients with endocrine therapy-relapsed advanced prostatic cancer. Seven trials were performed on 5 patients who received DESP (diethylstilbestrol diphosphate) (500 mg/body, day 1-5) with the chemotherapy. In 9 trials performed on 9 patients who did not receive DESP, there was no response case. In 7 trials with DESP, one trial had a partial response (PR) (14%) and 4 remained objectively stable (stable) (57%). As to adverse effects, myelosuppression was observed in all trials but there was no lethal toxicity. The one-year survival rate of these patients treated with the chemotherapy alone and combined DESP were both about 20%. Therefore we should find a more effective treatment for endocrine relapsed prostatic cancer. |
URI: | http://hdl.handle.net/2433/118014 |
PubMed ID: | 8285162 |
出現コレクション: | Vol.39 No.12 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。